Foghorn Therapeutics Inc. (FHTX) income statement
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30
$1.83+0.04 (+2.23%)
Close on Nov 17, 2026Market cap $108.68MP/E –Yield –
Foghorn Therapeutics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -198.0%
- Net margin
- -175.8%
- Return on equity, FY2025
- 96.5%
Financial strength
- Current ratio
- 3.36
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 134.6%
Valuation
- P/E ratio
- –
- Price to sales
- 2.96
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?